Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · January 23, 2022

Galcanezumab Well-Tolerated Up to 15 Months for Chronic Cluster Headache



Additional Info

Disclosure statements are available on the authors' profiles:

Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment
Headache 2021 Nov 22;[EPub Ahead of Print], MJA Láinez, J Schoenen, C Stroud, J Bardos, M Bangs, P Kemmer, R Wenzel, DK Kuruppu, JM Martinez, TM Oakes

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading